Arcus Biosciences (RCUS)

Executive Summary

Arcus Biosciences is a clinical-stage oncology company advancing a pipeline of rational combination therapies, anchored by its "Combining to Cure®" philosophy. The company's lead asset, casdatifan (HIF-2α inhibitor), is in a Phase 3 trial (NCT07011719) for metastatic clear cell renal cell carcinoma (ccRCC), with recruitment ongoing and expected completion by 2030. Arcus also has a broad portfolio of early- to mid-stage programs, including the anti-TIGIT antibody domvanalimab combined with the anti-PD-1 antibody zimberelimab across multiple indications (e.g., pancreatic cancer, melanoma) and the A2aR/A2bR antagonist etrumadenant in colorectal and gastroesophageal cancers. With a Phase 1/2 trial for pancreatic cancer (NCT05419479) and a Phase 2 study in rectal cancer (NCT05024097) actively recruiting, near-term catalysts could include interim data from these studies. The company's valuation of ~$2.9B reflects its potential in the immuno-oncology space, but high development risk remains given the early stage of most programs and competitive landscape. Arcus's fully integrated capabilities and proprietary discovery engine provide a foundation for future value creation, contingent on clinical results.

Upcoming Catalysts (preview)

• 2027Phase 3 casdatifan interim data in ccRCC60% success
• 2027Phase 1/2 data for domvanalimab + zimberelimab in pancreatic cancer50% success
• 2027Phase 2 data for etrumadenant combo in rectal cancer45% success